ºñ¿ëÁ¾ Ä¡·á ½ÃÀå : ¾àÁ¦ Ŭ·¡½ºº°, Åõ¿© °æ·Îº°, À¯Åë ä³Îº°, Áö¿ªº°
Nasal Polyps Treatment Market, By Drug Class, By Route of Administration, By Distribution Channel, By Geography
»óǰÄÚµå : 1673006
¸®¼­Ä¡»ç : Coherent Market Insights
¹ßÇàÀÏ : 2025³â 02¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹®
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,500 £Ü 6,217,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 7,000 £Ü 9,671,000
PDF (Multi User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 7¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 10,000 £Ü 13,817,000
PDF (Enterprise User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

ºñ¿ëÁ¾ Ä¡·á ¼¼°è ½ÃÀåÀº 2025³â¿¡ 36¾ï 5,000¸¸ ´Þ·¯, 2032³â¿¡´Â 61¾ï 9,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2025³âºÎÅÍ 2032³â±îÁö ¿¬Æò±Õ 7.8%ÀÇ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

º¸°í ¹üÀ§ º¸°í¼­ »ó¼¼ ³»¿ë
±âÁØ ¿¬µµ 2024³â 2025³â ½ÃÀå ±Ô¸ð 36¾ï 5,000¸¸ ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2020-2024³â ¿¹Ãø ±â°£ 2025-2032³â
¿¹Ãø ±â°£(2025-2032³â) CAGR 7.80% 2032³â °¡Ä¡ ¿¹Ãø 61¾ï 9,000¸¸ ´Þ·¯
±×¸². 2025³â Áö¿ªº° ºñ¿ëÁ¾ Ä¡·á ½ÃÀå Á¡À¯À²(%)
Nasal Polyps Treatment Market-IMG1

ºñ¿ëÁ¾ Ä¡·á ¼¼°è ½ÃÀåÀº ¸¸¼º ºÎºñµ¿¿°ÀÇ Àü ¼¼°è À¯º´·ü Áõ°¡·Î ÀÎÇØ °ý¸ñÇÒ ¸¸ÇÑ ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù. ºñ¿ëÁ¾Àº ºñ°­ ¹× ºÎºñµ¿ ³»º®¿¡ ¹ß»ýÇÏ´Â ºñ¾Ï¼º Áõ½ÄÀÔ´Ï´Ù. º¸Åë 40-60¼¼ ¼ºÀο¡°Ô ¹ßº´Çϸç, õ½Ä ȯÀÚ¿¡¼­ ¸¹ÀÌ ¹ß»ýÇÕ´Ï´Ù. À¯ÀüÀû ¼ÒÀΰú ȯ°æÀû ¾Ë·¹¸£°Õ µîÀÇ ¿äÀÎÀÌ ¹ßº´¿¡ °ü¿©ÇÒ ¼ö ÀÖ½À´Ï´Ù. ºñ¿ëÁ¾À» Ä¡·áÇÏÁö ¾Ê°í ¹æÄ¡Çϸé ÄÚ¸·Èû, Èİ¢ Àå¾Ö, ¾È¸é ¾Ð¹Ú°¨ ¹× ÅëÁõÀ» À¯¹ßÇÒ ¼ö ÀÖ½À´Ï´Ù. ±âÁ¸ Ä¡·á¹ýÀ¸·Î´Â ¾à¹°¿ä¹ý, ¼ö¼ú, °æ°ú °üÂû µîÀÌ ÀÖ½À´Ï´Ù. ÇÏÁö¸¸ ºÎÀÛ¿ëÀÌ ÀûÀº ½Å¾àÀÇ µîÀåÀ¸·Î ½ÃÀå ¼ºÀåÀÌ ±â´ëµÇ°í ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ

¼¼°è ºñ¿ëÁ¾ Ä¡·á ½ÃÀåÀ» Ȱ¼ºÈ­½ÃŰ´Â ÁÖ¿ä ÃËÁø¿äÀÎÀ¸·Î´Â ¸¸¼º ºÎºñµ¿¿°¿¡ Ãë¾àÇÑ ³ë·É Àα¸ Áõ°¡, ¾Ë·¹¸£±â À¯¹ß ȯ°æ ¿À¿° ¼öÁØ Áõ°¡, ÃÖ¼Ò Ä§½À ¼ö¼úÀÇ Ã¤Åà Áõ°¡ µîÀ» µé ¼ö ÀÖ½À´Ï´Ù. ±×·¯³ª ³ôÀº ¼ö¼ú ºñ¿ë°ú ½ÅÈï±¹¿¡¼­ÀÇ ÀÎ½Ä ºÎÁ·ÀÌ ½ÃÀå °³Ã´ÀÇ °É¸²µ¹·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. »õ·Î¿î Ç¥ÀûÄ¡·áÁ¦ ¹× º´¿ë¿ä¹ý °³¹ß¿¡´Â ºñÁî´Ï½º ±âȸ°¡ ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ºí·Ï¹ö½ºÅÍ ÀǾàǰÀÇ Æ¯Çã ¸¸·á°¡ ÀÓ¹ÚÇÔ¿¡ µû¶ó ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀå ÁøÀÔÀÇ ¿©Áöµµ ÀÖ½À´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

¼¼°èÀÇ ºñ¿ëÁ¾ Ä¡·á ½ÃÀå¿¡ ´ëÇØ Á¶»ç ºÐ¼®ÇßÀ¸¸ç, 2024³âÀ» ±âÁØ ¿¬µµ·Î ÇÏ¿© ¿¹Ãø ±â°£(2025-2032³â) ½ÃÀå ±Ô¸ð¿Í ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» Á¶»ç ºÐ¼®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.

¶ÇÇÑ, ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀû ¼öÀÍ Ã¢Ãâ ±âȸ¸¦ ÆÄ¾ÇÇϰí, ÀÌ ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¸¦ ¼³¸íÇÕ´Ï´Ù.

¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÇ °æÀï Àü·« µî¿¡ ´ëÇÑ ÁÖ¿ä °íÂûÀ» Á¦°øÇÕ´Ï´Ù.

±â¾÷ ÇÏÀ̶óÀÌÆ®, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ÇÏÀ̶óÀÌÆ®, ¼º°ú, Àü·« µîÀÇ ¸Å°³ º¯¼ö¸¦ ±â¹ÝÀ¸·Î ¼¼°è ºñ¿ëÁ¾ Ä¡·á ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏÀ» Á¦°øÇÕ´Ï´Ù.

ÁÖ¿ä ±â¾÷À¸·Î´Â »ç³ëÇÇ, ¸ÓÅ©, ¾Æ½ºÆ®¶óÁ¦³×Ä«, ¸®Á¦³×·Ð, ³ë¹ÙƼ½º, ¿ÉƼ³ë½º, GSK plc, ÀÎÅͼ½Æ® À̺ñÀÎÈİú(INTERSECT ENT, Inc.), ½ã ÆÄ¸¶½´Æ¼Äà Àδõ½ºÆ®¸®Áî(Sun Pharmaceutical Industries Ltd.), Cipla, Mylan N.V., Genentech µîÀÌ ÀÖ½À´Ï´Ù. Mylan N.V., Genentech µîÀÌ ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­ÀÇ ÅëÂû·ÂÀ» ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° Ãâ½Ã, À¯ÇüÈ­, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü¼ú¿¡ ´ëÇÑ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.

¼¼°è ºñ¿ëÁ¾ Ä¡·á ½ÃÀå º¸°í¼­´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô ½ÃÀå ÁøÃâ±â¾÷, À繫 ºÐ¼®°¡ µî ÀÌ ¾÷°èÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¸ñÀû°ú ÀüÁ¦Á¶°Ç

Á¦2Àå ½ÃÀå Àü¸Á

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

Á¦4Àå ¼¼°èÀÇ ºñ¿ëÁ¾ Ä¡·á ½ÃÀå, ¾àÁ¦ Ŭ·¡½ºº°, 2020³â-2032³â(10¾ï ´Þ·¯)

Á¦5Àå ¼¼°èÀÇ ºñ¿ëÁ¾ Ä¡·á ½ÃÀå, Åõ¿© °æ·Îº°, 2020³â-2032³â(10¾ï ´Þ·¯)

Á¦6Àå ¼¼°èÀÇ ºñ¿ëÁ¾ Ä¡·á ½ÃÀå, À¯Åë ä³Îº°, 2020³â-2032³â(10¾ï ´Þ·¯)

Á¦7Àå ¼¼°èÀÇ ºñ¿ëÁ¾ Ä¡·á ½ÃÀå, Áö¿ªº°, 2020³â-2032³â, ±Ý¾×(10¾ï ´Þ·¯)

Á¦8Àå °æÀï ±¸µµ

Á¦9Àå ¾Ö³Î¸®½ºÆ® Ãßõ »çÇ×

Á¦10Àå Âü°í ¹®Çå°ú Á¶»ç ¹æ¹ý

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Nasal Polyps Treatment Market is estimated to be valued at USD 3.65 Bn in 2025 and is expected to reach USD 6.19 Bn by 2032, growing at a compound annual growth rate (CAGR) of 7.8% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 3.65 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 7.80% 2032 Value Projection: USD 6.19 Bn
Figure. Nasal Polyps Treatment Market Share (%), By Region 2025
Nasal Polyps Treatment Market - IMG1

The global nasal polyps treatment market has been witnessing significant growth due to the rising prevalence of chronic sinusitis worldwide. Nasal polyps are non-cancerous growths that develop in the lining of the nasal cavities or sinuses. They usually affect adults aged between 40 and 60 years and are more common in people with asthma. Factors such as genetic predisposition and environmental allergens can contribute to their development. If left untreated, nasal polyps can cause nasal obstruction, loss of smell, and facial pressure or pain. The existing treatment options include drug therapies, surgery, and watchful monitoring. However, the market is expected to witness growth in the emergence of new drugs with fewer side effects.

Market Dynamics:

The key drivers fueling the global nasal polyps treatment market include the growing geriatric population's susceptibility to chronic sinusitis, rising environmental pollution levels triggering allergies, and increasing adoption of minimally invasive surgeries. However, the high cost of surgery and lack of awareness in developing nations are restricting market growth. Opportunities lie in the development of novel targeted drug therapeutics and combinational therapies. The upcoming patent expiries of blockbuster drugs also allow scope for biosimilar market entries.

Key Features of the Study:

This report provides in-depth analysis of the global nasal polyps treatment market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global nasal polyps treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Sanofi, Merck & Co., Inc., AstraZeneca, Regeneron Pharmaceuticals Inc., Novartis AG, Optinose, GSK plc., INTERSECT ENT, Inc., Sun Pharmaceutical Industries Ltd., Cipla, Mylan N.V., and Genentech

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

The global nasal polyps treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Market Segmentation

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Nasal Polyps Treatment Market, By Drug Class, 2020-2032, (USD Bn)

5. Global Nasal Polyps Treatment Market, By Route of Administration, 2020-2032, (USD Bn)

6. Global Nasal Polyps Treatment Market, By Distribution Channel, 2020-2032, (USD Bn)

7. Global Nasal Polyps Treatment Market, By Region, 2020 - 2032, Value (USD Bn)

8. Competitive Landscape

9. Analyst Recommendations

10. References and Research Methodology

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â